Schizophrenia Epidemiology Forecast

DelveInsight’s ‘Schizophrenia—Epidemiology Forecast–2030’ report delivers an in-depth understanding of the disease, historical and forecasted Schizophrenia epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Schizophrenia Understanding

Schizophrenia is a serious mental disorder in which people interpret reality abnormally. Schizophrenia may result in some combination of hallucinations, delusions, and extremely disordered thinking and behavior that impairs daily functioning, and can be disabling.


Schizophrenia is typically diagnosed in the late teen years to the early thirties and tends to emerge earlier in males (late adolescence – early twenties) than females (early twenties – early thirties). A diagnosis of Schizophrenia often follows the first episode of psychosis, when individuals first display symptoms of Schizophrenia. Gradual changes in thinking, mood, and social functioning often begin before the first episode of psychosis, usually starting in mid-adolescence. Schizophrenia can occur in younger children, but it is rare for it to occur before late adolescence. The most common form is paranoid Schizophrenia, or Schizophrenia with paranoia, as it’s often called. People with paranoid Schizophrenia have an altered perception of reality. They may see or hear things that don’t exist, speak in strange or confusing ways, believe that others are trying to harm them, or feel like they’re being constantly watched. This can cause relationship problems, disrupt normal daily activities like bathing, eating, or running errands, and lead to alcohol and drug abuse in an attempt to self-medicate.

Schizophrenia Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalent Cases of Schizophrenia, Diagnosed Prevalent cases of Schizophrenia, Gender-specific Diagnosed Prevalent cases of Schizophrenia, Age-specific Diagnosed Prevalent cases of Schizophrenia, and Severity-specific Diagnosed Prevalent cases of Schizophrenia scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Schizophrenia Detailed Epidemiology Segmentation

  • Total prevalent population of Schizophrenia in the 7MM was 5,969,144 in 2020. These cases of Schizophrenia in the 7MM is expected to increase throughout the study period, i.e., 2018–2030.
  • Total diagnosed prevalent population of Schizophrenia in the 7MM was observed to be 3,043,148 in 2020.
  • Among the European five countries, Germany has the highest diagnosed prevalent population followed by the United Kingdom and France. On the other hand, Spain had the lowest diagnosed prevalent population.
  • In the epidemiology model of Schizophrenia, there are multiple age groups referred ranging from 18-24 Years; 25-34 Years; 35-44 Years; 45-54 Years; 55-64 Years and 65+ Years for Schizophrenia in the US. The highest was 371,697 in the age group 35-44 Years, in 2020, in the US.
  • Men with Schizophrenia appear to have more negative symptoms and more severe clinical features than females, particularly in social withdrawal, substance abuse, and blunted or incongruent affects than female patients.
  • In 2020, the diagnosed prevalent population of mild Schizophrenia was 317,745, which accounted for 22.00% of the total diagnosed cases of Schizophrenia, in the United States.


According to DelveInsight, the majority of cases of Schizophrenia are male as compared to female, in the US and EU-5. But in Japan the diagnosed cases of females represents majority of the cases.

Scope of the Report

  • The report covers the descriptive overview of Schizophrenia, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Schizophrenia.
  • The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of Schizophrenia, Total Diagnosed and Treated Cases of Schizophrenia.

Report Highlights

  • 10-Year Forecast of Schizophrenia
  • 7MM Coverage
  • Prevalent Cases of Schizophrenia in 7MM
  • Diagnosed Prevalent cases of Schizophrenia in 7MM
  • Gender-specific Diagnosed Prevalent cases of Schizophrenia in 7MM
  • Age-specific Diagnosed Prevalent cases of Schizophrenia in 7MM
  • Severity-specific Diagnosed Prevalent cases of Schizophrenia in 7MM

Key Questions Answered

  • What is the disease risk, burden and unmet needs of Schizophrenia?
  • What is the historical Schizophrenia patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Schizophrenia at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Schizophrenia?
  • Out of the countries mentioned above, which country would have the highest prevalent population of Schizophrenia during the forecast period (2021–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2021–2030)?

Reasons to buy

The Schizophrenia report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM Schizophrenia market.
  • The Schizophrenia epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
  • The Schizophrenia epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. Executive Summary of Schizophrenia

4. Disease Background and Overview

4.1. Introduction

4.2. Early warning signs and symptoms of Schizophrenia

4.3. Risk factors of Schizophrenia

4.4. Subtypes of Schizophrenia

4.5. Mechanism of Schizophrenia

4.6. Genetics of Schizophrenia

4.7. Diagnosis

4.8. Differential Diagnosis

4.9. Treatment and Management

4.9.1. Acute-phase symptoms

4.9.1.1. Pre-treatment assessment

4.9.2. Medication (Antipsychotic)

4.9.3. Psychotherapy

4.9.4. Psychosocial Therapy

4.9.5. Electroconvulsive Therapy (ECT)

4.9.6. IPAP Schizophrenia Algorithm

4.9.7. Treatment guidelines

4.9.7.1. The American Psychiatric Association (APA) practice guideline for the treatment of patients with Schizophrenia

4.9.7.2. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations

4.9.7.3. Updated Schizophrenia port treatment recommendations: psychosocial treatment recommendations

5. Epidemiology and Patient Population

5.1. Key Findings

5.2. Epidemiology Methodology

5.3. Total Prevalent Cases of Schizophrenia in the 7MM

5.4. Total Diagnosed Prevalent Cases of Schizophrenia in the 7MM

5.5. United States Epidemiology

5.5.1. Assumptions and Rationale

5.5.2. Prevalent Cases of Schizophrenia in the United States

5.5.3. Diagnosed prevalent cases of Schizophrenia in the United States

5.5.4. Gender-specific Diagnosed Prevalent cases of Schizophrenia in the United States

5.5.5. Age-specific Diagnosed Prevalent cases of Schizophrenia in the United States

5.5.6. Severity-specific Diagnosed Prevalent cases of Schizophrenia in the United States

5.6. EU5 Epidemiology

5.6.1. Germany Epidemiology

5.6.1.1. Assumptions and Rationale

5.6.1.2. Prevalent Cases of Schizophrenia in Germany

5.6.1.3. Diagnosed prevalent cases of Schizophrenia in Germany

5.6.1.4. Gender-specific Diagnosed Prevalent cases of Schizophrenia in Germany

5.6.1.5. Age-specific Diagnosed Prevalent cases of Schizophrenia in Germany

5.6.1.6. Severity-specific Diagnosed Prevalent cases of Schizophrenia in Germany

5.6.2. France Epidemiology

5.6.2.1. Assumptions and Rationale

5.6.2.2. Prevalent Cases of Schizophrenia in France

5.6.2.3. Diagnosed Prevalent cases of Schizophrenia in France

5.6.2.4. Gender-specific Diagnosed Prevalent cases of Schizophrenia in France

5.6.2.5. Age-specific Diagnosed Prevalent cases of Schizophrenia in France

5.6.2.6. Severity-specific Diagnosed Prevalent cases of Schizophrenia in France

5.6.3. Italy Epidemiology

5.6.3.1. Assumptions and Rationale

5.6.3.2. Prevalent Cases of Schizophrenia in Italy

5.6.3.3. Diagnosed Prevalent cases of Schizophrenia in Italy

5.6.3.4. Gender-specific Diagnosed Prevalent cases of Schizophrenia in Italy

5.6.3.5. Age-specific Diagnosed Prevalent cases of Schizophrenia in Italy

5.6.3.6. Severity-specific Diagnosed Prevalent cases of Schizophrenia in Italy

5.6.4. Spain Epidemiology

5.6.4.1. Assumptions and Rationale

5.6.4.2. Prevalent Cases of Schizophrenia in Spain

5.6.4.3. Diagnosed prevalent cases of Schizophrenia in Spain

5.6.4.4. Gender-specific Diagnosed Prevalent cases of Schizophrenia in Spain

5.6.4.5. Age-specific Diagnosed Prevalent cases of Schizophrenia in Spain

5.6.4.6. Severity-specific Diagnosed Prevalent cases of Schizophrenia in Spain

5.6.5. United Kingdom Epidemiology

5.6.5.1. Assumptions and Rationale

5.6.5.2. Prevalent Cases of Schizophrenia in the UK

5.6.5.3. Diagnosed Prevalent cases of Schizophrenia in the UK

5.6.5.4. Gender-specific Diagnosed Prevalent cases of Schizophrenia in the UK

5.6.5.5. Age-specific Diagnosed Prevalent cases of Schizophrenia in the UK

5.6.5.6. Severity-specific Diagnosed Prevalent cases of Schizophrenia in the UK

5.7. Japan Epidemiology

5.7.1. Assumptions and Rationale

5.7.2. Prevalent Cases of Schizophrenia in Japan

6.7.3. Diagnosed Prevalent cases of Schizophrenia in Japan

5.7.4. Gender-specific Diagnosed Prevalent cases of Schizophrenia in Japan

5.7.5. Age-specific Diagnosed Prevalent cases of Schizophrenia in Japan

5.7.6. Severity-specific Diagnosed Prevalent cases of Schizophrenia in Japan

6. KOL Views

7. Appendix

7.1. Bibliography

7.2. Report Methodology

8. DelveInsight Capabilities

9. Disclaimer

10. About DelveInsight

List of Table

Table 1: Summary of Schizophrenia, Epidemiology and Key Events (2017–2030)

Table 2: Early symptoms of Schizophrenia

Table 3: Symptoms of Schizophrenia

Table 4: Clinical features of Schizophrenia, bipolar disorder, schizoaffective disorder, autism, and ADHD

Table 5: Antipsychotic medications: available oral and short-acting intramuscular formulations and dosing considerations

Table 6: Long-acting injectable antipsychotic medications: dosing

Table 7: Total Prevalent Cases of Schizophrenia in the 7MM, in Thousand (2018–2030)

Table 8: Total Diagnosed Prevalent Cases of Schizophrenia in the 7MM, in Thousand (2018–2030)

Table 9: Prevalent cases of Schizophrenia in the United States, in Thousand (2018–2030)

Table 10: Diagnosed Prevalent cases of Schizophrenia in the United States, in Thousand (2018–2030)

Table 11: Gender-specific Diagnosed Prevalent cases of Schizophrenia in the US, in Thousand (2018–2030)

Table 12: Age-specific Diagnosed Prevalent cases of Schizophrenia in the US, in Thousand (2018–2030)

Table 13: Severity-specific Diagnosed Prevalent cases of Schizophrenia in the US, in Thousand (2018–2030)

Table 14: Prevalent cases of Schizophrenia in Germany, in Thousand (2018–2030)

Table 15: Diagnosed Prevalent cases of Schizophrenia in Germany, in Thousand (2018–2030)

Table 16: Gender-specific Diagnosed Prevalent cases of Schizophrenia in Germany, in Thousand (2018–2030)

Table 17: Age-specific Diagnosed Prevalent cases of Schizophrenia in Germany, in Thousand (2018–2030)

Table 18: Severity-specific Diagnosed Prevalent cases of Schizophrenia in Germany, in Thousand (2018–2030)

Table 19: Prevalent cases of Schizophrenia in France, in Thousand (2018–2030)

Table 20: Diagnosed Prevalent cases of Schizophrenia in France, in Thousand (2018–2030)

Table 21: Gender-specific Diagnosed Prevalent cases of Schizophrenia in France, in Thousand (2018–2030)

Table 22: Age-specific Diagnosed Prevalent cases of Schizophrenia in Germany, in Thousand (2018–2030)

Table 23: Severity-specific Diagnosed Prevalent cases of Schizophrenia in France, in Thousand (2018–2030)

Table 24: Prevalent cases of Schizophrenia in Italy, in Thousand (2018–2030)

Table 25: Diagnosed Prevalent cases of Schizophrenia in Italy, in Thousand (2018–2030)

Table 26: Gender-specific Diagnosed Prevalent cases of Schizophrenia in Italy, in Thousand (2018–2030)

Table 27: Age-specific Diagnosed Prevalent cases of Schizophrenia in Italy, in Thousand (2018–2030)

Table 28: Severity-specific Diagnosed Prevalent cases of Schizophrenia in Italy, in Thousand (2018–2030)

Table 29: Prevalent cases of Schizophrenia in Spain, in Thousand (2018–2030)

Table 30: Diagnosed Prevalent cases of Schizophrenia in Spain, in Thousand (2018–2030)

Table 31: Gender-specific Diagnosed Prevalent cases of Schizophrenia in Spain, in Thousand (2018–2030)

Table 32: Age-specific Diagnosed Prevalent cases of Schizophrenia in Spain, in Thousand (2018–2030)

Table 33: Severity-specific Diagnosed Prevalent cases of Schizophrenia in Spain, in Thousand (2018–2030)

Table 34: Prevalent cases of Schizophrenia in the UK, in Thousand (2018–2030)

Table 35: Diagnosed Prevalent cases of Schizophrenia in the UK, in Thousand (2018–2030)

Table 36: Gender-specific Diagnosed Prevalent cases of Schizophrenia in the UK, in Thousand (2018–2030)

Table 37: Age-specific Diagnosed Prevalent cases of Schizophrenia in the UK, in Thousand (2018–2030)

Table 38: Severity-specific Diagnosed Prevalent cases of Schizophrenia in the UK, in Thousand (2018–2030)

Table 39: Prevalent cases of Schizophrenia in Japan, in Thousand (2018–2030)

Table 40: Diagnosed Prevalent cases of Schizophrenia in Japan, in Thousand (2018–2030)

Table 41: Gender-specific Diagnosed Prevalent cases of Schizophrenia in Japan, in Thousand (2018–2030)

Table 42: Age-specific Diagnosed Prevalent cases of Schizophrenia in Japan, in Thousand (2018–2030)

Table 43: Severity-specific Diagnosed Prevalent cases of Schizophrenia in Japan, in Thousand (2018–2030)

List of Figures

Figure 1: Overview of Schizophrenia

Figure 2: Interaction of genetic and environmental risk factors in the developmental pathology of Schizophrenia

Figure 3: Neuron–glia interactions in the cerebral cortex—key neural substrates for the pathology of Schizophrenia

Figure 4: Schematic representation of drug actions that normalize aberrant glutamate neurotransmission in the prefrontal cortex of schizophrenics

Figure 5: A representative molecular pathway for Schizophrenia—fine-tuning of the glutamate synapse

Figure 6: Treatment approaches of Schizophrenia

Figure 7: Types of medications to treat Schizophrenia

Figure 8: Types of Psychotherapy to treat Schizophrenia

Figure 9: Schizophrenia Algorithm

Figure 10: Total Prevalent Cases of Schizophrenia in the 7MM, in Thousand (2018–2030)

Figure 11: Total Diagnosed Prevalent Cases of Schizophrenia in the 7MM, in Thousand (2018–2030)

Figure 12: Prevalent cases of Schizophrenia in the United States, in Thousand (2018–2030)

Figure 13: Diagnosed Prevalent cases of Schizophrenia in the United States, in Thousand (2018–2030)

Figure 14: Gender-specific Diagnosed Prevalent cases of Schizophrenia in the US, in Thousand (2018–2030)

Figure 15: Age-specific Diagnosed Prevalent cases of Schizophrenia in the US, in Thousand (2018–2030)

Figure 16: Severity-specific Diagnosed Prevalent cases of Schizophrenia in the US, in Thousand (2018–2030)

Figure 17: Prevalent cases of Schizophrenia in Germany, in Thousand (2018–2030)

Figure 18: Diagnosed Prevalent cases of Schizophrenia in Germany, in Thousand (2018–2030)

Figure 19: Gender-specific Diagnosed Prevalent cases of Schizophrenia in Germany, in Thousand (2018–2030)

Figure 20: Age-specific Diagnosed Prevalent cases of Schizophrenia in Germany, in Thousand (2018–2030)

Figure 21: Severity-specific Diagnosed Prevalent cases of Schizophrenia in Germany, in Thousand (2018–2030)

Figure 22: Prevalent cases of Schizophrenia in France, in Thousand (2018–2030)

Figure 23: Diagnosed Prevalent cases of Schizophrenia in France, in Thousand (2018–2030)

Figure 24: Gender-specific Diagnosed Prevalent cases of Schizophrenia in France, in Thousand (2018–2030)

Figure 25: Age-specific Diagnosed Prevalent cases of Schizophrenia in Germany, in Thousand (2018–2030)

Figure 26: Severity-specific Diagnosed Prevalent cases of Schizophrenia in France, in Thousand (2018–2030)

Figure 27: Prevalent cases of Schizophrenia in Italy, in Thousand (2018–2030)

Figure 28: Diagnosed Prevalent cases of Schizophrenia in Italy, in Thousand (2018–2030)

Figure 29: Gender-specific Diagnosed Prevalent cases of Schizophrenia in Italy, in Thousand (2018–2030)

Figure 30: Age-specific Diagnosed Prevalent cases of Schizophrenia in Italy, in Thousand (2018–2030)

Figure 31: Severity-specific Diagnosed Prevalent cases of Schizophrenia in Italy, in Thousand (2018–2030)

Figure 32: Prevalent cases of Schizophrenia in Spain, in Thousand (2018–2030)

Figure 33: Diagnosed Prevalent cases of Schizophrenia in Spain, in Thousand (2018–2030)

Figure 34: Gender-specific Diagnosed Prevalent cases of Schizophrenia in Spain, in Thousand (2018–2030)

Figure 35: Age-specific Diagnosed Prevalent cases of Schizophrenia in Spain, in Thousand (2018–2030)

Figure 36: Severity-specific Diagnosed Prevalent cases of Schizophrenia in Spain, in Thousand (2018–2030)

Figure 37: Prevalent cases of Schizophrenia in the UK, in Thousand (2018–2030)

Figure 38: Diagnosed Prevalent cases of Schizophrenia in the UK, in Thousand (2018–2030)

Figure 39: Gender-specific Diagnosed Prevalent cases of Schizophrenia in the UK, in Thousand (2018–2030)

Figure 40: Age-specific Diagnosed Prevalent cases of Schizophrenia in the UK, in Thousand (2018–2030)

Figure 41: Severity-specific Diagnosed Prevalent cases of Schizophrenia in the UK, in Thousand (2018–2030)

Figure 42: Prevalent cases of Schizophrenia in Japan, in Thousand (2018–2030)

Figure 43: Diagnosed Prevalent cases of Schizophrenia in Japan, in Thousand (2018–2030)

Figure 44: Gender-specific Diagnosed Prevalent cases of Schizophrenia in Japan, in Thousand (2018–2030)

Figure 45: Age-specific Diagnosed Prevalent cases of Schizophrenia in Japan, in Thousand (2018–2030)

Figure 46: Severity-specific Diagnosed Prevalent cases of Schizophrenia in Japan, in Thousand (2018–2030)

  • Tags:
  • Schizophrenia Epidemiology
  • Schizophrenia
  • Schizophrenia Pipeline
  • Schizophrenia Companies
  • Schizophrenia prevalent population
  • Schizophrenia incident population
  • Schizophrenia patients diagnosed
  • Schizophrenia treatment algorithm

Forward to Friend

Need A Quote